HC Wainwright & Co. Reiterates Buy on RAPT Therapeutics, Maintains $41 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on RAPT Therapeutics (NASDAQ:RAPT) and maintained a $41 price target for the company's stock.
November 15, 2023 | 11:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RAPT Therapeutics maintains a Buy rating and a $41 price target from HC Wainwright & Co., potentially influencing investor confidence and stock performance.
The reiteration of a Buy rating and maintenance of a $41 price target by a reputable analyst could lead to increased investor confidence and a positive short term impact on RAPT's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100